|Conditional recommendation based on moderate-quality evidence; may consider an IL-12/23i biologic if the patient has concomitant IBD or prefers less frequent drug administration.| |
|8. Switch to an IL-17i biologic over abatacept (PICO 69)|Low (89–95, 103, 104)|
|Conditional recommendation based on low-quality evidence; may consider abatacept in patients with recurrent or serious infections.| |
|9. Switch to an IL-17i biologic over tofacitinib (PICO 78)|Low (89–95, 105)|